244 related articles for article (PubMed ID: 25159135)
21. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
22. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
23. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
Onishi H; Shirato H; Nagata Y; Hiraoka M; Fujino M; Gomi K; Karasawa K; Hayakawa K; Niibe Y; Takai Y; Kimura T; Takeda A; Ouchi A; Hareyama M; Kokubo M; Kozuka T; Arimoto T; Hara R; Itami J; Araki T
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1352-8. PubMed ID: 20638194
[TBL] [Abstract][Full Text] [Related]
25. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
[No Abstract] [Full Text] [Related]
29. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
30. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
Bezjak A; Paulus R; Gaspar LE; Timmerman RD; Straube WL; Ryan WF; Garces YI; Pu AT; Singh AK; Videtic GM; McGarry RC; Iyengar P; Pantarotto JR; Urbanic JJ; Sun AY; Daly ME; Grills IS; Sperduto P; Normolle DP; Bradley JD; Choy H
J Clin Oncol; 2019 May; 37(15):1316-1325. PubMed ID: 30943123
[TBL] [Abstract][Full Text] [Related]
32. Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent.
Brown WT; Wu X; Fayad F; Fowler JF; García S; Monterroso MI; de la Zerda A; Schwade JG
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):623-31. PubMed ID: 19682875
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.
Senthi S; Haasbeek CJ; Slotman BJ; Senan S
Radiother Oncol; 2013 Mar; 106(3):276-82. PubMed ID: 23462705
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
Fakiris AJ; McGarry RC; Yiannoutsos CT; Papiez L; Williams M; Henderson MA; Timmerman R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):677-82. PubMed ID: 19251380
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
[TBL] [Abstract][Full Text] [Related]
37. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
Guckenberger M; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N
J Thorac Oncol; 2013 Aug; 8(8):1050-8. PubMed ID: 23817193
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity.
Duncker-Rohr V; Nestle U; Momm F; Prokic V; Heinemann F; Mix M; Reusch J; Messmer MB; Marschner N; Waller CF; Weber WA; Grosu AL
Strahlenther Onkol; 2013 Jan; 189(1):33-40. PubMed ID: 23179248
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
